Eesti - eesti - Ravimiamet

veyx-pharma gmbh - gonadoreliin - süstelahus - 50mcg 1ml 10ml 1tk; 50mcg 1ml 20ml 1tk; 50mcg 1ml 50ml 1tk

Eesti - eesti - Ravimiamet

ceva sante animale - gonadoreliin - süstelahus - 50mcg 1ml 4ml 1tk; 50mcg 1ml 10ml 1tk; 50mcg 1ml 20ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

anamorelin vesinikkloriid - cachexia; anorexia; carcinoma, non-small-cell lung - kõik muud ravitoimingud - ravi anoreksia, cachexia või tahtmatu kaalulangus täiskasvanud patsientidel, kellel non-small cell lung cancer (mitteväikerakk-kopsuvähi).

Eesti - eesti - Ravimiamet

ferring a/s - gonadoreliin - süstelahus - 100mcg 1ml 1ml 1tk

Eesti - eesti - Ravimiamet

aventis - gonadoreliin - süstelahus - 100mcg 1ml 1ml 10tk

Eesti - eesti - Ravimiamet

ferring gmbh - gonadoreliin - süstelahus - 0,1mg 1ml 1ml 1tk

Eesti - eesti - Ravimiamet

laboratoires juvise pharmaceuticals - bikalutamiid - õhukese polümeerikattega tablett - 50mg 28tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

n.v. organon - korifollitropiin alfa - reproductive techniques, assisted; ovulation induction; investigative techniques - suguhormoonid ja genitaalsüsteemi, - controlled ovarian stimulation (cos) in combination with a gnrh antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (art) program. elonva is indicated for the treatment of adolescent males (14 to less than 18 years and older) with hypogonadotropic hypogonadism, in combination with human chorionic gonadotropin (hcg).

Euroopa Liit - eesti - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - eesnäärmevähk - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Euroopa Liit - eesti - EMA (European Medicines Agency)

zoetis belgium sa - synthetic peptide analogue of gnrf conjugated to diptheria toxoid - sigalaste immunoloogilised omadused - male pigs (from 8 weeks of age); female pigs (from 14 weeks of age) - male pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of testicular function. for use as an alternative to physical castration for the reduction of boar taint caused by the key boar taint compound androstenone, in entire male pigs following the onset of puberty. kahjuritõrjemeetodi, vitoolooli teise olulise osakaalu võib ka vähendada kui kaudset mõju. samuti vähenevad agressiivsed ja seksuaalsed (paigaldus) käitumised. female pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of ovarian function (suppression of oestrus) in order to reduce the incidence of unwanted pregnancies in gilts intended for slaughter, and to reduce the associated sexual behaviour (standing oestrus).